Kornimate/medical-research-clean huggingface dataset:
trauma-focused equine-assisted therapy (tf-eat) for veterans with ptsd

Conditions: Posttraumatic Stress Disorder

Summary: this study seeks to examine feasibility, acceptability, safety, and preliminary efficacy of equine-assisted therapy for veterans with posttraumatic stress disorder (eat-ptsd). while several well-studied, validated treatments for ptsd exist, some individuals find these treatments ill-suited, ineffective, or undesirable. eat is an alternative therapy widely used by organizations, such as path international equine services, that endorse its effectiveness for treating a variety of mental health issues. these claims have drawn criticism because the published research contains glaring methodological flaws, making it difficult to assess how effective these therapies actually are (anestis et al., 2014). equine-assisted therapies present a unique treatment modality that might effectively treat ptsd, particularly for individuals who have difficulty with other treatment modalities. in eat, a psychotherapist and equine specialist work together to help the patients negotiate interactions with a horse using structured interventions or activities.

in this pilot study the investigators will develop the eat intervention and determine whether research methods (evaluation interviews, assessment measures, videotaping procedures) are acceptable to participants. specifically, the investigators will focus on issues such as session length, appropriateness of the "content" for treatment of ptsd, ordering of session content, adherence to the manual of the equine therapeutic team (based on observations made during supervision and feedback from the consultants), and will detail logistics of data collection and how best to record the sessions (camera angles, etc.).

Eligibility criteria:
inclusion criteria: * between the ages of 18 and 70 * current dsm-5 diagnosis of ptsd as determined by a) full criteria met on caps, and b) clinical assessment * able to give consent, fluent in english exclusion criteria: * history of psychiatric diagnosis of psychotic disorder, unstable bipolar disorder * elevated depression of clinical concern and/or score of \>25 on the hamilton rating scale for depression * at elevated risk for suicide based on history and current mental state * history of substance/alcohol use disorder at severe level within the past six months, and current diagnosis of substance/alcohol use disorder at a moderate level within past two months * fear of horses or other large animals * orthopedic or other physical conditions and/or limitations that prevent people from walking unassisted and/or walking freely in the ring.
prolonged adjuvant temozolomide vs "stop & go" in glioblastoma patients

Conditions: Glioblastoma

Summary: this study will test the hypothesis that prolonged adjuvant temozolomide (tmz) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain mri every 3 months and rechallenging with tmz at relapse (stop and go arm).


Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed diagnosis of gbm 2. availability of pre-treatment gbm tissue to determine the activation status of mgmt gene is not mandatory but strongly recommended 3. patients must have received radiation and tmz for 6 weeks followed by 6 months of tmz. randomization should be performed within the 6 weeks after the last chemotherapy. 4. a brain mri with or without a pet-scan-methionine must be performed before enrolment. 5. age ≥ 18 years 6. karnofsky performance status ≥ 60 7. normal haematological functions: anc ≥ 1.5 x 109cells/l, platelets ≥ 100 x 109 cells/l 8. normal liver function: total bilirubin \< 1.5 x uln, alkaline phosphatase and transaminases (asat/alat) \< 2.5 times the upper limit of the normal range 9. serum creatinine \< 1.5 x uln 10. clinically normal cardiac function without history of ischemic heart disease in the past 12 months. absence of cardiac insufficiency nyha grade iii and iv, instable angina, arrhythmia 11. no previous or current malignancy (except treated basal or squamous cell skin carcinoma, cervix cancer or in situ carcinoma of the breast). 12. all patients (male and female) with reproductive potential must use effective contraception. females must have a negative serum pregnancy test at entry to study. 13. signed informed consent from the patient or legal representative must be obtained. exclusion criteria: all non inclusion criteria

Keywords: temozolomide phase ii chemotherapy glioblastoma progression-free survival
immune profiling during ocrelizumab treatment in multiple sclerosis

Conditions: Multiple Sclerosis; Healthy

Summary: the purpose of this study is to assess effects of b cell depletion on the immune system in patients with relapsing forms of multiple sclerosis (ms) treated with ocrelizumab. this will be done by collecting blood from patients starting treatment with ocrelizumab before the first infusion and before the infusions at 6 and 12 months. the effects on the immune system will be assessed by performing transcriptome profiling of immune cells, measuring serum levels of micrornas, and analyzing serum autoantibody immune signatures using antigen arrays. in addition, blood will be collected once from a group of healthy individuals to serve as controls.


Eligibility criteria:
inclusion criteria: * patients with relapsing form of ms starting treatment with ocrelizumab at partners ms center * healthy controls * ability to understand and sign informed consent exclusion criteria - all subjects: * other concomitant autoimmune or inflammatory diseases * ongoing treatment with other immunomodulatory medications * previous treatment with rituximab, methotrexate, cyclophosphamide, mitoxantrone, mycophenolate mofetil, or alemtuzumab * pregnancy or lactation * hypersensitivity to ocrelizumab exclusion criteria - healthy controls: * ms * first-degree relatives with ms
intervention for employed women with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: unemployment is particularly common among women with multiple sclerosis (ms). this study uses a vocational rehabilitation program involving neuropsychological testing as an intervention. the use of in-person feedback and case management following neuropsychological testing is compared to phone feedback only. adherence to treatment and employment outcomes will be evaluated over three years.

employed women at a tertiary-care ms center were screened for common issues impacting work productivity (fatigue, cognitive dysfunction, and depression). women who met screening criteria were randomized to one of two treatment groups: either neuropsychological testing and phone feedback to review findings and tailored recommendations (standard-care treatment); or neuropsychological testing, in-person feedback, and two calls from a care-coordinator (experimental treatment). adherence to recommendations and employment status at one year are evaluated. follow-up periods also occur at year two and year three.

Eligibility criteria:
inclusion criteria: * female sex * age between 18 and 64 * employed at least 20 hours per week * confirmed diagnosis of ms exclusion criteria: * experiencing an ms exacerbation * endorsing suicidal ideation or intent * pregnant * severe psychiatric disorder * history of traumatic brain injury * dementia * major neurological illness other than ms

Keywords: employment vocational rehabilitation
effect of oxygen supplementation during exercise in chronic obstructive pulmonary disease patients

Conditions: Chronic Obstructive Pulmonary Disease; Hypoxia

Summary: the project will test the hypothesis that lung ventilation during exercise is unaffected by oxygen supplementation. in addition, the acute effect of oxygen supplementation on dyspnoea, heart rate and blood pressure will be studied.


Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease exclusion criteria: * no exacerbation * no active heart disease
different neural circuit mechanisms between cognitive therapy and behavior therapy for patients with panic disorder: a dynamic research

Conditions: Panic Disorder

Summary: cognitive behavioral therapy (cbt), which includes cognitive therapy (ct) and behavioral therapy (bt), is the first-line treatment for patients with panic disorder (pd). however, the neural mechanism of cbt is unknown. the exploration of mechanism is of great significance for clinical strategy formulation. this study is proposed on the basis of our early pd and cbt neuroimaging studies, adopt the design of prospective randomized controlled intervention study, set up three time points: before the treatment（week 0）, the initial treatment (week 4th), the plateau treatment (week 28th). with normal subjects as black control and antidepressant therapy as intervention comparison, this study set up ct and bt two intervention groups, respectively collect all the participants'symptomatological, psychological, cognitive function and brain imaging data (3d,dti, fmri in resting and tasks states) at week 0, week 4th and week 28th. this study is based on the advanced analysis methods we applied in the early study,including bold-fmri, dti, topological characteristics analysis of the whole brain network and granger causality test etc. it is from the point of multiple levels(brain regions, circuits, whole brain), multimodal (structure, function) to comprehensively analysis the role of ct and bt for the function and structure of brain regions, circuits (mood regulating circuit and cognitive control network for emotion processing) and whole brain in patients with pd. totally, we explore the target area, path and mechanism of cbt for emotion processing neural circuits in patients with pd, and combined with the clinical data we preliminarily explore the imaging biomarkers of different intervention methods which may predict therapeutic effect.


Eligibility criteria:
inclusion criteria: * meet dsm-5 and mini-international neuropsychiatric interview (mini) chinese version panic disorder diagnosis; * the age of 20-50 years old; * right handedness; * patients to participate voluntarily, with the consent of their families, signed informed consent book. exclusion criteria: * neurological diseases or other mental illnesses; * serious physical illness (e.g. heart, lung, liver, kidney or blood system disease); * treatment by psychotropic medications,psychological treatment, electroconvulsive therapy or physical therapy within 3 months prior to the start of the trial; * with contraindication for mri * pregnancy and lactation.

Keywords: cognitive-behavior therapy magnetic resonance imaging panic disorder
brief skills training intervention for suicidal individuals

Conditions: Suicide

Summary: a significant percentage of individuals who die by suicide do not seek mental health services in the time preceding their death. this population is underserved and it is unclear what barriers keep them from seeking treatment. in order to begin a line of research aimed at addressing this high-risk population, this proposal rests on the hypothesis that suicidal individuals who do not seek treatment prior to attempting suicide experience the same psychopathological difficulties as suicidal individuals who do seek treatment - namely, severe emotion dysregulation. however, these non-treatment-seeker s will likely require more creative recruitment strategies and briefer interventions than treatment-seeking individuals. as such, this application proposes to use wide-reaching recruitment efforts throughout the community to locate and enroll individuals who are suicidal but not seeking treatment. further, there is a paucity of empirical support for interventions targeting suicidal individuals. dialectical behavior therapy (dbt) is one of the few treatments that have been demonstrated to be effective with a suicidal population and is the only treatment whose effectiveness has been replicated. previous research has suggested that an abbreviated version of the skills that are taught in dbt skills training have effectively reduced emotion dysregulation (i.e., depression and anxiety) in problem drinkers and the format of the proposed intervention is derived from this evidence-based emotion dysregulation intervention. as such, the proposed research is a randomized, controlled pilot trial of a very brief, one-time, skills-based intervention targeting difficulties in emotion regulation and distress tolerance. this research aims to evaluate the safety of the intervention, the feasibility of the research methods (including the appropriateness of the relaxation training control condition), and to preliminarily estimate the immediate (one week) and long-term (one and three month) changes resulting from the dbt brief skills intervention (dbt-bsi) relative to a relaxation training control on the primary outcomes of suicide ideation and emotion dysregulation as well as a number of secondary outcomes. these results will inform the design of a subsequent full-scale randomized controlled trial of the dbt-bsi.


Eligibility criteria:
inclusion criteria: * 18+ years old * suicidal ideation in the last week * live within commuting distance to research office * have not been engaged in mental health treatment in the past month * consent to assessment exclusion criteria: * non-english speaking * significant cognitive impairment
real world patient characteristics and treatment patterns from crizanlizumab use: preliminary analysis from select sickle cell centers

Conditions: Sickle Cell Disease

Summary: this was a retrospective cohort study using secondary data from member sites of the national alliance of sickle cell centers (nascc) with patients who had initiated crizanlizumab between 2019 and 2022.


Eligibility criteria:
inclusion criteria * any patient with a diagnosis of scd based on high performance liquid chromatography (hplc) or hemoglobin electrophoresis at treating institution. * treatment order for crizanlizumab; index date was defined as the date for the first crizanlizumab treatment. * at least 12 months of available electronic medical record (emr) data pre-index date (baseline). * patients must have received at least one dose of crizanlizumab. * for inclusion in pre/post analysis of effectiveness, patients must have received crizanlizumab for at least 12 months. exclusion criteria none identified.
effect of epinephrine/ phenylephrine for preventing the postreperfusion syndrome during reperfusion in liver transplantation

Conditions: Hypotension After Reperfusion in Liver Transplantation

Summary: postreperfusion syndrome (prs) is a relatively common phenomenon in patients undergoing liver transplantation which is characterized by an acute drop in blood pressure immediately after the prefusion is restored to the transplanted liver. we hypothesized that prs would be prevented when phenylephrine or epinephrine is administered immediately prior to reperfusion in liver transplantation.


Eligibility criteria:
inclusion criteria: - adults scheduled to undergo liver transplantation exclusion criteria: - pediatric liver transplantation

Keywords: postreperfusion syndrome phenylephrine epinephrine liver transplantation
remote conditioning in out-of-hospital cardiac arrest

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: out-of-hospital cardiac arrest remains a major public health problem, resulting in high mortality largely related to multiple organ failure and poor neurological outcomes due to brain anoxia. the pathophysiology of organ dysfunction after resuscitated out-of-hospital cardiac arrest involves ischemia-reperfusion processes. remote ischemic conditioning is a therapeutic strategy used to protect organs against the detrimental effects of ischemia-reperfusion injury. the objective of the present trial is to determine whether remote ischemic conditioning performed early after out-of-hospital cardiac arrest can decrease mortality, or multiple organ failure and/or severe neurological failure.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years old * out-of-hospital cardiac arrest, whatever the initial cardiac rhythm (shockable or non-shockable) or the duration of no-flow and low-flow, * presence of a witness who may or may not have started cardiopulmonary resuscitation, or patient seen alive in the 30 minutes prior to the cardiac arrest, * hospitalisation in critical care (intensive care unit or cardiac intensive care unit) for less than 3 hours, * informed consent obtained from a close relative (exceptionally from the patient himself if his condition permits) or, failing this, use of the emergency procedure by the investigator. exclusion criteria: * traumatic cardiac arrest * patient on extracorporeal circulatory assistance * cardiac arrest for which continuation of resuscitation does not appear justified (unavoidable death, terminal stage of an irreversible disease, etc.) * contraindication of the use of brachial cuff on both arms (arteriovenous fistula, lymphoedema or severe peripheral vascular pathology, unstable humeral fracture, continuous infusion into an upper limb vein of an essential drug such as a catecholamine, radial arterial catheter for continuous invasive measurement of blood pressure) * pregnant, parturient, or breast-feeding women * patients deprived of their liberty by a judicial or administrative decision, * patients under legal protection (guardianship, curatorship), * patient not affiliated to a social security scheme or beneficiary of a similar scheme, * previous inclusion in the study, * subject participating in other interventional research that may interfere with the present study according to the investigator's judgement or that includes an exclusion period still in progress at inclusion

Keywords: out-of-hospital cardiac arrest remote conditioning ischemic conditioning ischemia-reperfusion intensive care unit
immune responses in hen's egg oral immunotherapy

Conditions: Food Allergy; Egg Protein Allergy; Immune Tolerance

Summary: the study determines how a 6 months oral immunotherapy (oit) program with hen's egg (he) effects cellular and humoral immune responses in 50 children with he allergy. clinical data, transcriptomics and epigenetics are combined and analyzed by advanced system biology methods. this study will provide better understanding of the effects and mechanisms of oit.

oral immunotherapy (oit) is a therapeutic approach, where gradually increasing doses of a specific food allergen are administered orally. oit can desensitize up to 80% of children with persistent food allergy, and in a subset lead to sustained immune tolerance. the immunologic mechanisms induced by oit are still poorly understood. in this randomized cross-over study, 50 children with challenge-confirmed hen's egg (he) allergy will be randomized (2:1) to receive either active he oit or continue on an avoidance diet for 6 months after which active oit is started. the immunological changes induced by oit will be compared to the patient's initial status and to that of the patients on an avoidance diet. serum antibody and humoral mediator analyses as well as gene expression of blood mononuclear cell (pbmc) by genome-wide microarray assays will be studied. pbmcs will be stimulated with he allergens and innate immunity agonists, and the differences in the expression profiles of messenger-rnas as well as micrornas will be studied. single-cell sequencing and sorting of regulator t cells (tregs) will be performed focusing on their transcriptomic responses and gene methylation. finally, clinical data, transcriptomics and epigenetic changes will be combined and analyzed by advanced system biology methods. this study will provide better understanding of the effects and mechanisms of oit and identify biomarkers for selection of patients benefitting from personalized oit.

Eligibility criteria:
inclusion criteria: 1. age 6-19 years 2. sensitization to egg white (egg white- specific ige ≥0.35 ku/l or skin prick test ≥3 mm) 3. positive double-blind, placebo-controlled food challenge to heated egg white exclusion criteria: 1. poor adherence 2. uncontrolled or severe asthma 3. severe systemic illness 4. active autoimmune disease 5. active, malignant neoplasia

Keywords: food allergy hen's egg allergy desensitization oral immunotherapy (oit) systems biology
vamikibart in participants with uveitic macular edema

Conditions: Uveitic Macular Edema

Summary: this study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.


Eligibility criteria:
inclusion criteria: * female participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol * diagnosis of macular edema associated with non-infectious uveitis (niu) * diagnosis of active or inactive, acute, or chronic niu of any etiology and of any anatomical type (anterior, intermediate, posterior, panuveitis) * bcva letter score of 73 to 19 letters (inclusive) on early treatment diabetic retinopathy study (edtrs)-like charts exclusion criteria: * evidence of active or latent syphilis infection * evidence of active or latent tuberculosis infection and/or positive tuberculosis assay, or previous or current hiv diagnosis * serious acute or chronic medical or psychiatric illness * history of major ocular and non-ocular surgical procedures * uncontrolled iop or glaucoma or chronic hypotony * any anatomical changes or media opacity in the study eye preventing evaluation of retina, vitreous, and capture of study images * prior use of ivt biologics including anti-vegfs less than 2-4 months prior to day 1; received ivt methotrexate within 4 months prior to day 1 * prior macular laser therapy, cataract surgery within 6 months and laser capsulotomy within 3 months of day 1 * topical corticosteroids and/or topical nsaid \> 3 drops per day in the 14 days prior to day 1 (d1); intraocular or periocular corticosteroid injections in the 2 months prior to d1; subconjunctival corticosteroid injection within 1 month prior to day 1; an ozurdex implant in the 4 months prior to d1; yutiq, retisert or iluvien implant in the 3 years prior to d1 * diagnosis of macular edema due to any cause other than niu * any major ocular conditions that may require medical or surgical intervention during the study period to prevent vision loss